NCT03478397 Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project) Status COMPLETED Phase NA
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma Status TERMINATED Phase PHASE2
NCT03458455 Improved Therapy Response Assessment in Metastatic Brain Tumors Status ACTIVE_NOT_RECRUITING Phase N/A
NCT03455764 MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Status COMPLETED Phase PHASE1/PHASE2
NCT03447886 Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds Status COMPLETED Phase N/A
NCT03436654 Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03425331 Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC Status TERMINATED Phase PHASE2
NCT03422003 Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma Status ACTIVE_NOT_RECRUITING Phase NA
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03410875 A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03392246 A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03391362 Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases Status ACTIVE_NOT_RECRUITING Phase NA
NCT03367247 BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal Status COMPLETED Phase NA
NCT03364673 Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer Status COMPLETED Phase NA
NCT03361852 Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1